Clearmind Medicine Inc (CMND)

$1.03 0.00 (N/A)
Market Cap 4.39M
Revenue (ttm) 0.00
Net Income (ttm) -5.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 24,200
Avg Vol 68,512
Day's Range N/A - N/A
Shares Out 4.27M
Stochastic %K 10%
Beta 0.94
Analysts Strong Buy
Price Target N/A

Latest News on CMND

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

Apr 1, 2025, 8:15 AM EDT - 2 days ago

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

Mar 21, 2025, 9:28 AM EDT - 13 days ago

Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Mar 19, 2025, 7:35 AM EDT - 15 days ago

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

Mar 18, 2025, 7:32 AM EDT - 16 days ago

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

Feb 4, 2025, 8:35 AM EST - 2 months ago

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

Clearmind Medicine Announces Shareholders Meeting Results

Jan 7, 2025, 9:28 AM EST - 3 months ago

Clearmind Medicine Announces Shareholders Meeting Results

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025, 8:15 AM EST - 3 months ago

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office

Jan 2, 2025, 7:45 AM EST - 3 months ago

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Dec 26, 2024, 6:59 AM EST - 3 months ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

Dec 24, 2024, 6:55 AM EST - 3 months ago

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

Dec 16, 2024, 8:37 AM EST - 3 months ago

Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

Oct 10, 2024, 8:07 AM EDT - 6 months ago

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Sep 16, 2024, 4:06 PM EDT - 7 months ago

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment

Sep 12, 2024, 8:20 AM EDT - 7 months ago

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Sep 6, 2024, 7:55 AM EDT - 7 months ago

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment

Aug 29, 2024, 4:25 PM EDT - 7 months ago

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

Aug 21, 2024, 4:11 PM EDT - 8 months ago

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

Aug 16, 2024, 4:14 PM EDT - 8 months ago

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug

Aug 6, 2024, 8:57 AM EDT - 8 months ago

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research

Jul 31, 2024, 7:44 AM EDT - 8 months ago

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

Jul 19, 2024, 7:55 AM EDT - 9 months ago

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism

Jul 16, 2024, 9:02 AM EDT - 9 months ago

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Jul 16, 2024, 6:03 AM EDT - 9 months ago

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

Jul 12, 2024, 8:02 AM EDT - 9 months ago

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

Jun 28, 2024, 7:55 AM EDT - 9 months ago

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

Jun 20, 2024, 7:57 AM EDT - 10 months ago

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

Jun 11, 2024, 7:44 AM EDT - 10 months ago

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

May 10, 2024, 8:24 AM EDT - 11 months ago

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

May 7, 2024, 7:46 AM EDT - 11 months ago

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

Clearmind Applies to Cease Being a Reporting Issuer in Canada

Apr 30, 2024, 4:15 PM EDT - 1 year ago

Clearmind Applies to Cease Being a Reporting Issuer in Canada

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

Apr 17, 2024, 7:49 AM EDT - 1 year ago

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Apr 10, 2024, 7:17 AM EDT - 1 year ago

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Clearmind Medicine CEO Issues Letter to Shareholders

Apr 9, 2024, 8:07 AM EDT - 1 year ago

Clearmind Medicine CEO Issues Letter to Shareholders

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Mar 27, 2024, 9:12 AM EDT - 1 year ago

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

Mar 19, 2024, 7:55 AM EDT - 1 year ago

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

CSE Bulletin: Delist - Clearmind Medicine Inc. (CMND)

Mar 13, 2024, 2:55 PM EDT - 1 year ago

CSE Bulletin: Delist - Clearmind Medicine Inc. (CMND)

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Mar 13, 2024, 8:14 AM EDT - 1 year ago

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

Mar 13, 2024, 7:30 AM EDT - 1 year ago

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

Feb 27, 2024, 7:58 AM EST - 1 year ago

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Feb 23, 2024, 7:06 AM EST - 1 year ago

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Feb 20, 2024, 7:14 AM EST - 1 year ago

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Feb 5, 2024, 7:51 AM EST - 1 year ago

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

Feb 1, 2024, 8:15 AM EST - 1 year ago

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)

Jan 16, 2024, 12:20 PM EST - 1 year ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement

Jan 16, 2024, 11:19 AM EST - 1 year ago

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement

Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement

Jan 11, 2024, 9:28 AM EST - 1 year ago

Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement

Clearmind Medicine Completed Type A Meeting with the FDA

Jan 10, 2024, 7:18 AM EST - 1 year ago

Clearmind Medicine Completed Type A Meeting with the FDA

Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments

Jan 4, 2024, 7:18 AM EST - 1 year ago

Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments

Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards

Dec 14, 2023, 8:26 AM EST - 1 year ago

Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards

Clearmind Medicine Inc (CMND) is the goose that got cooked – trade carefully

Dec 6, 2023, 9:24 AM EST - 1 year ago

Clearmind Medicine Inc (CMND) is the goose that got cooked – trade carefully